LIVE · 41 SOURCES
News Activity Log Weather Economy Municipal 🏙 Blindspot Divergence Owners 🏢 MPs 🏛 Cost of Parliament 💵 Markets 📈 Accountability Chain 🔗 Cross-Watch 🔗 Team Governance Methodology Score Education API Subscribe to What The Fact Sign in →
Montreal Gazette 🏢 Postmedia 📍 QC May 16, 2026 · 1 min read AI Analyzed View full audit trail → C.R.E.E.D. audited

Dr. Reddy’s Laboratories Launches its Generic Semaglutide Injection in Canada

Original article ↗ 🔒 Paywalled source — limited preview available
B.I.A.S. ANALYSIS
CENTER
LEFTCENTERRIGHT
Signal breakdown
Heuristic (v1/v3) 0.00 · CENTER
ML v2 (DistilBERT) 0.000 · CENTER
Ensemble 0.000 · CENTER
🏦 Source Intelligence
🏢 Corporate · Postmedia
CA
Rolling outlet bias
CENTER
avg -0.054
2,788 articles tracked
7-day bias trend
LcenterR
Article Excerpt
The launch follows Dr. Reddy’s receipt of the Notice of Compliance (NOC) from Health Canada on April 28th, 2026, marking the company’s readiness to serve Canadian patients Dr. Reddy’s is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada Canada is the first G7 country to grant market authorization for...
Read full article at Montreal Gazette ↗
How we scored this article

WTF uses a two-tier system: every article gets a heuristic bias score from keyword analysis, and priority articles (high overlap across 3+ outlets or strong heuristic signal) get full LLM analysis from B.I.A.S. and V.E.R.I.F.Y.

Full audit trail for this article →

Analyzed by
B.I.A.S. V.E.R.I.F.Y. L.O.C.A.L. quick v1 + full Jun 6, 2026